Calcium alpha-ketoglutarate (Ca-AKG) trials recruiting now
2 registrations that name calcium alpha-ketoglutarate as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
RecruitingNCT04723888
Alpha-Ketoglutarate and Abdominal Aortic Aneurysm Progression and Rupture
No phase
RenJi Hospital
About 300 people
Started Feb 1, 2021
In plain words A study of calcium alpha-ketoglutarate in people 50 and older, run by RenJi Hospital. It plans to enroll about 300 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 and older. Conditions: Patients With an Abdominal Aortic Aneurysm of 39-49 mm in Diameter.
Presence of an infrarenal AAA with a maximum diameter of 39-49 mm;
Han nationality;
Between 50 years or more, no gender limit;
No mental illness;
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
alpha-ketoglutarate
Registered summary
The objective of this project is to define whether nutritional supplement (oral administration with alpha-ketoglutarate) capable of filling-up the citric acid cycle (anaplerotic therapy) can improve outcomes in patients with an abdominal aortic aneurysm of 39-49 mm in diameter on ultrasound imaging. Alpha-ketoglutarate is commonly used as a nutritional supplement specially by athletes to increase muscle strength. They can be mixed with formula or other foods. Subjects will be followed for up to 5 years.
Where, as registered
No US site; China (1).
RecruitingNCT07031128
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)
Phase 4
National University Hospital, Singapore
About 250 people
Started Jun 11, 2024
In plain words A Phase 4 study of calcium alpha-ketoglutarate in people 50 and older, run by National University Hospital, Singapore. It plans to enroll about 250 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 and older. Conditions: CABG.
Scheduled for elective CABG with cardiopulmonary bypass
Aged 50 years and above
Adequate cognitive function to be able to give informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Alpha-ketoglutarate; Placebo
Registered summary
One of the most common major surgeries that older patients undergo is coronary artery bypass grafting surgery (CABG), which is performed in approximately 400,000 patients in the United States each year. CABG invokes a massive surgical stress response, with systemic epinephrine increasing 33-fold and norepinephrine increasing 3-fold. Initially, local tissue injury results in a sterile inflammation, releasing damage-associated molecular patterns (DAMPS). DAMPS activate neutrophils, bringing a cascade of cytokines, complement, and coagulation changes. The full summary is on the listing.
Where, as registered
No US site; Singapore (2).
ClinicalTrials.gov lists 3 open registrations for this search, including ones where calcium alpha-ketoglutarate is not a study arm or that are past the 2 we keep. Search them on ClinicalTrials.gov (opens in new tab).